Outcomes After Delayed Primary Percutaneous Coronary Intervention Vs. Pharmaco-invasive Strategy in ST-segment Elevation Myocardial Infarction in Norway
Overview
Affiliations
Aims: Primary percutaneous coronary intervention (pPCI) is the preferred reperfusion strategy in patients with ST-segment elevation myocardial infarction (STEMI) provided it can be performed within 120 min from diagnosis. However, it is unclear whether pPCI or a pharmaco-invasive (P-I) strategy is the best choice in patients who cannot receive timely pPCI. The aim of the present study was to compare outcomes after delayed and late pPCI vs. a P-I strategy in STEMI patients who did not receive timely pPCI.
Methods And Results: All patients with STEMI registered in the Norwegian Myocardial Infarction Registry (NORMI) between 2013 and 2019, with ≤12 h from symptom onset to first medical contact and available timelines were included in the study. The primary outcome was all-cause mortality, and follow-up was through 2019. A total of 21 121 (27% of 78 368) STEMI patients were registered in the NORMI. Among patients who met the inclusion criteria, 7238 (54%) patients underwent timely pPCI, 1537 (11%) delayed pPCI (121-180 min), 1012 (7%) late pPCI (>180 min), and 2338 (17%) patients were treated with a P-I strategy. After a median follow-up time of 2.5 years, mortality was higher in the delayed pPCI [adjusted hazard ratio (HR) 1.3, 95% confidence interval (CI) 1.0-1.5] and in the late pPCI group (adjusted HR 1.4, 95% CI 1.1-1.7) compared to the P-I strategy group, but bleeding complications were more frequent after P-I strategy.
Conclusions: In STEMI patients who did not receive timely percutaneous coronary intervention, a P-I strategy seemed to be associated with better long-term survival compared to delayed/late pPCI.
Ethnic Disparities of Arrival Following ST Elevation Myocardial Infarction in South Israel.
Zeldetz V, Nevzorov R, Weissberg I, Jotkowitz A, Shamia D, Slutsky T J Clin Med. 2024; 13(21).
PMID: 39518653 PMC: 11546267. DOI: 10.3390/jcm13216516.
Dou J, Gao J, Yang H, Guo R, Jiang C, Zhou J Clin Appl Thromb Hemost. 2024; 30:10760296241271394.
PMID: 39140859 PMC: 11325463. DOI: 10.1177/10760296241271394.
Uleberg B, Bonaa K, Govatsmark R, Olsen F, Jacobsen B, Stensland E BMJ Open. 2024; 14(2):e081301.
PMID: 38367969 PMC: 10875564. DOI: 10.1136/bmjopen-2023-081301.
Time trends in incidence, treatment, and outcome in acute myocardial infarction in Norway 2013-19.
Jortveit J, Pripp A, Langorgen J, Halvorsen S Eur Heart J Open. 2022; 2(5):oeac052.
PMID: 36071696 PMC: 9442850. DOI: 10.1093/ehjopen/oeac052.
Li K, Zhang B, Zheng B, Zhang Y, Huo Y Front Cardiovasc Med. 2022; 9:813325.
PMID: 35369319 PMC: 8970601. DOI: 10.3389/fcvm.2022.813325.